KALVISTA PHARMACEUTICALS INC's ticker is KALV and the CUSIP is 483497103. A total of 93 filers reported holding KALVISTA PHARMACEUTICALS INC in Q2 2022. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $4,953,066 | -59.0% | 732,702 | -12.0% | 0.26% | -63.4% |
| Q3 2022 | $12,083,000 | +51.1% | 832,702 | +2.4% | 0.70% | +50.3% |
| Q2 2022 | $7,998,000 | +1211.1% | 812,828 | +1863.7% | 0.46% | +2225.0% |
| Q1 2022 | $610,000 | +12.1% | 41,393 | +0.7% | 0.02% | 0.0% |
| Q4 2021 | $544,000 | +42.0% | 41,087 | +87.2% | 0.02% | +66.7% |
| Q3 2021 | $383,000 | -19.9% | 21,948 | +10.0% | 0.01% | -20.0% |
| Q2 2021 | $478,000 | -8.1% | 19,956 | -1.5% | 0.02% | 0.0% |
| Q1 2021 | $520,000 | – | 20,257 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Stonepine Capital Management, LLC | 422,310 | $10,849,000 | 5.86% |
| COMMODORE CAPITAL LP | 214,467 | $5,510,000 | 2.20% |
| Vivo Capital, LLC | 1,863,296 | $47,868,000 | 1.68% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 214,533 | $5,486,000 | 1.45% |
| Nicholas Investment Partners, LP | 594,130 | $15,263,000 | 1.06% |
| Altium Capital Management LP | 128,130 | $3,292,000 | 0.91% |
| Affinity Asset Advisors, LLC | 100,000 | $2,569,000 | 0.87% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 50,000 | $1,285,000 | 0.70% |
| APIS CAPITAL ADVISORS, LLC | 30,000 | $771,000 | 0.70% |
| Birchview Capital, LP | 40,000 | $1,028,000 | 0.61% |